MedTrace Logo

Double Trigger in Patients With Low Proportion of Mature Oocytes

NCT04407052 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2020-05-29

No results posted yet for this study

Summary

The aim of this randomized controlled trial is to determine whether co-administration of GnRH agonist and hCG for final oocyte maturation ( 40 and 34 h prior to oocyte retrieval , respectively) can increase the number of mature oocytes in patients with history of low proportion of mature oocytes in previous IVF cycle triggered by HCG.

Conditions

  • Infertility, Female

Interventions

DRUG

Double trigger

Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively

DRUG

HCG trigger

Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval

Sponsors & Collaborators

  • Riyadh Fertility and Reproductive Health center

    lead OTHER

Principal Investigators

  • Usama M Fouda, Prof. · Riyadh Fertility and Reproductive Health center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-30
Primary Completion
2020-12-31
Completion
2021-02-02

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04407052 on ClinicalTrials.gov